Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

Date
2020
Author
Guler, Emine Nilufer
Demir, Atakan
Mandel, Nil Molinas
PAYDAŞ, SEMRA
Demir, Gokhan
ER, Ozlem
Turhal, Nazim Serdal
Bavbek, Sevil
Eralp, Yesim
Saip, Pinar Mualla
Aydiner, Adnan
OYAN ULUÇ, Başak
Kilickap, Sadettin
Uskent, Necdet
Karadurmus, Nuri
Kaplan, Mehmet Ali
Yanmaz, Mustafa Teoman
Demir, Hacer
Alan, Ozkan
KORKMAZ, Taner
Olgun, Polat
Uysal, Ozlem Sonmez
Altundag, Kadri
Gunduz, Seyda
Gunaldi, Meral
Sari, Murat
Beypinar, Ismail
BAŞARAN, Gül
Metadata
Show full item record
Abstract
Background: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood.
URI
http://hdl.handle.net/20.500.12627/60714
https://doi.org/10.4274/balkanmedj.galenos.2020.2019.11.143
Collections